Citations

Showing 10 of 108081 citations.

Incidentally Discovered Right Atrial Mass: A Rare and Unexpected Etiology
Sykora, Daniel , Chaliki, Hari P. , Cummings, Kristopher W. , Stanton, Melissa, Scott, Luis R. , Sell-Dottin, Kristen, Stanton, Melissa L, Sell‐Dottin, Kristen

Mayo Clinic

Texas Heart Institute Journal | April 15, 2023 | Volume: 50 | Issue: 2 | Pages: No page available

10.14503/thij-21-7735 | PMID 37060553 Get It

Abstract Primary cardiac sarcoma is a rare type of intracardiac mass. This report describes a patient with atrial flutter who had a new right atrial mass incidentally discovered on transesophageal echocardiography. A thrombus was suspected based on radiographic appearance, but there was minimal change with anticoagulation. The mass was resected and found to be an undifferentiated pleomorphic cardiac sarcoma, an uncommon sub-type within the already rare category of primary cardiac neoplasms. This report highlights the importance of considering primary malignancy and thoroughly correlating radiographic and clinical evidence during the diagnostic workup of patients with intracardiac masses.
Impact of opioids on esophageal motility
Snyder, Diana L. , Vela, Marcelo F.

Mayo Clinic

Neurogastroenterology & Motility | April 15, 2023 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/nmo.14587 | PMID 37060333 Get It

AbstractOpioids are well known to cause adverse effects on the gastrointestinal tract including nausea, vomiting, and constipation. Data regarding how opioids affect the esophagus are more limited. Opioid‐induced esophageal dysfunction (OIED) is a clinical syndrome defined by chronic opioid use (≥3 months), esophageal symptoms (mainly dysphagia), and esophageal motility abnormalities diagnosed by manometry including achalasia type III, hypercontractile esophagus, distal esophageal spasm, and esophagogastric junction outflow obstruction. Up until now, the effect of opioids on esophageal motility assessed by the functional lumen imaging probe (FLIP) had not been described. In this issue of NGM, Patel et al. report that FLIP assessment in patients with esophageal symptoms showed that chronic opioid users have a significant increase in repetitive retrograde contractions, but no significant reduction in distensibility at the esophagogastric junction compared to non‐users. Additionally, perceptive symptoms were higher, and quality of life metrics were lower in the chronic opioid users. This review article will discuss our current understanding of OIED and provide context for this latest study in chronic opioid users. Further investigation with larger prospective studies is needed to understand the pathophysiology, diagnosis, and management of OIED.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
Weiner, Adam B. , Hakansson, Alex, Zhao, Xin , Proudfoot, James A. , Ho, Julian, Zhang, JJ H., Li, Eric V. , Karnes, R. Jeffrey , Kishan, Amar U. , Reiter, Robert E. , Hamid, Anis , Ross, Ashely E., Spratt, Daniel E. , Chua, Melvin L.K. , Sweeney, Christopher J. , Schaeffer, Edward M. , Li, Eric V , Hamid, Anis A , Spratt, Daniel E , Sweeney, Christopher , Chua, Melvin L K , Liu, Yang , Den, Robert B. , Ross, Ashely E., Tran, Phuoc T , Davicioni, Elai , Attard, Gerhardt , Lotan, Tamara Levin , Zhang, JJ H.

Mayo Clinic

Cancer | April 15, 2023 | Volume: 129 | Issue: 14 | Pages: 2169-2178

10.1002/cncr.34790 | PMID 37060201 Get It

AbstractBackgroundProstate cancer (PCa) is a clinically heterogeneous disease. The creation of an expression‐based subtyping model based on prostate‐specific biological processes was sought.MethodsUnsupervised machine learning of gene expression profiles from prospectively collected primary prostate tumors (training, n = 32,000; evaluation, n = 68,547) was used to create a prostate subtyping classifier (PSC) based on basal versus luminal cell expression patterns and other gene signatures relevant to PCa biology. Subtype molecular pathways and clinical characteristics were explored in five other clinical cohorts.ResultsClustering derived four subtypes: luminal differentiated (LD), luminal proliferating (LP), basal immune (BI), and basal neuroendocrine (BN). LP and LD tumors both had higher androgen receptor activity. LP tumors also had a higher expression of cell proliferation genes, MYC activity, and characteristics of homologous recombination deficiency. BI tumors possessed significant interferon γactivity and immune infiltration on immunohistochemistry. BN tumors were characterized by lower androgen receptor activity expression, lower immune infiltration, and enrichment with neuroendocrine expression patterns. Patients with LD tumors had less aggressive tumor characteristics and the longest time to metastasis after surgery. Only patients with BI tumors derived benefit from radiotherapy after surgery in terms of time to metastasis (hazard ratio [HR], 0.09; 95% CI, 0.01–0.71; n = 855). In a phase 3 trial that randomized patients with metastatic PCa to androgen deprivation with or without docetaxel (n = 108), only patients with LP tumors derived survival benefit from docetaxel (HR, 0.21; 95% CI, 0.09–0.51).ConclusionsWith the use of expression profiles from over 100,000 tumors, a PSC was developed that identified four subtypes with distinct biological and clinical features.Plain language summary Prostate cancer can behave in an indolent or aggressive manner and vary in how it responds to certain treatments. To differentiate prostate cancer on the basis of biological features, we developed a novel RNA signature by using data from over 100,000 prostate tumors—the largest data set of its kind. This signature can inform patients and physicians on tumor aggressiveness and susceptibilities to treatments to help personalize cancer management.
Seizure occurrence is linked to multiday cycles in diverse physiological signals
Gregg, Nicholas M. , Attia, Tal Pal , Nasseri, Mona , Karoly, Philippa J. , Cui, Jie , Stirling, Rachel E. , Viana, Pedro F. , Nurse, Ewan S. , Cook, Mark , Richardson, Mark P. , Brinkmann, Benjamin H. , Pal Attia, Tal , Joseph, Boney , Karoly, Phillipa J , Cui, Jie , Stirling, Rachel E , Viana, Pedro F , Richner, Thomas J, Nurse, Ewan , Schulze-Bonhage, Andreas , Cook, Mark J , Worrell, Gregory A , Richardson, Mark P , Freestone, Dean R , Brinkmann, Benjamin H , Gregg, Nicholas M , Joseph, Boney , Richner, Thomas J. , Schulze‐Bonhage, Andreas , Worrell, Gregory A. , Freestone, Dean R.

Mayo Clinic

Epilepsia | April 15, 2023 | Volume: 64 | Issue: 6 | Pages: 1627-1639

10.1111/epi.17607 | PMID 37060170 Get It

Abstract Objective The factors that influence seizure timing are poorly understood, and seizure unpredictability remains a major cause of disability. Work in chronobiology has shown that cyclical physiological phenomena are ubiquitous, with daily and multiday cycles evident in immune, endocrine, metabolic, neurological, and cardiovascular function. Additionally, work with chronic brain recordings has identified that seizure risk is linked to daily and multiday cycles in brain activity. Here, we provide the first characterization of the relationships between the cyclical modulation of a diverse set of physiological signals, brain activity, and seizure timing. Methods In this cohort study, 14 subjects underwent chronic ambulatory monitoring with a multimodal wrist‐worn sensor (recording heart rate, accelerometry, electrodermal activity, and temperature) and an implanted responsive neurostimulation system (recording interictal epileptiform abnormalities and electrographic seizures). Wavelet and filter–Hilbert spectral analyses characterized circadian and multiday cycles in brain and wearable recordings. Circular statistics assessed electrographic seizure timing and cycles in physiology. Results Ten subjects met inclusion criteria. The mean recording duration was 232 days. Seven subjects had reliable electroencephalographic seizure detections (mean = 76 seizures). Multiday cycles were present in all wearable device signals across all subjects. Seizure timing was phase locked to multiday cycles in five (temperature), four (heart rate, phasic electrodermal activity), and three (accelerometry, heart rate variability, tonic electrodermal activity) subjects. Notably, after regression of behavioral covariates from heart rate, six of seven subjects had seizure phase locking to the residual heart rate signal. Significance Seizure timing is associated with daily and multiday cycles in multiple physiological processes. Chronic multimodal wearable device recordings can situate rare paroxysmal events, like seizures, within a broader chronobiology context of the individual. Wearable devices may advance the understanding of factors that influence seizure risk and enable personalized time‐varying approaches to epilepsy care.
Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition
Pinto, Marcus Vinícius , França, Marcondes C. , Gonçalves, Marcus Vinícius Magno , Machado‐Costa, Marcela Câmara , Gondim, Francisco de Assis Aquino , Marrone, Carlo Domênico , Martínez, Alberto , Moreira, Carolina Lavigne , Nascimento, Osvaldo J. M. , Covaleski, Anna Paula Paranhos Miranda , Pupe, Camila , Rotta, Francisco Tellechea , Scola, Rosana Hermínia , Marques, Wilson , França, Marcondes Cavalcante , Freitas, Marcos Raimundo Gomes de , Gondim, Francisco de Assis Aquino , Marrone, Carlo Domenico , Martinez, Alberto Rolim Muro , Moreira, Carolina Lavigne , Nascimento, Osvaldo J M , Covaleski, Anna Paula Paranhos , Oliveira, Acary Souza Bulle de , Pupe, Camila Castelo Branco , Rodrigues, Marcia Maria Jardim , Rotta, Francisco Tellechea , Scola, Rosana Herminia , Marques, Wilson , Waddington-Cruz, Márcia , Pinto, Marcus V , Waddington‐Cruz, Márcia

Mayo Clinic

Arquivos de Neuro-Psiquiatria | April 14, 2023 | Volume: 81 | Issue: 03 | Pages: 308-321

10.1055/s-0043-1764412 | PMID 37059440 Get It

AbstractHereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN) is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy with over 130 pathogenic variants identified in the TTR gene. Hereditary transthyretin amyloidosis with peripheral neuropathy is a disabling, progressive and life-threatening genetic condition that leads to death in ∼ 10 years if untreated. The prospects for ATTRv-PN have changed in the last decades, as it has become a treatable neuropathy. In addition to liver transplantation, initiated in 1990, there are now at least 3 drugs approved in many countries, including Brazil, and many more are being developed. The first Brazilian consensus on ATTRv-PN was held in the city of Fortaleza, Brazil, in June 2017. Given the new advances in the area over the last 5 years, the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology organized a second edition of the consensus. Each panelist was responsible for reviewing the literature and updating a section of the previous paper. Thereafter, the 18 panelists got together virtually after careful review of the draft, discussed each section of the text, and reached a consensus for the final version of the manuscript.
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials
Bhatt, Vijaya Raj , Ulrich, Angela M. , Uy, Geoffrey L. , Stone, Richard M. , Stock, Wendy , Ojelabi, Michael Olayiwola , Yin, Jun , Kohlschmidt, Jessica, Eisfeld, Ann‐Kathrin , Baer, Maria R. , Chow, Selina , Jatoi, Aminah , Ojelabi, Michael O , Klepin, Heidi D , Le-Rademacher, Jennifer G , Stock, Wendy , Bhatt, Vijaya Raj , Uy, Geoffrey , Klepin, Heidi D. , Le‐Rademacher, Jennifer

Mayo Clinic

JCO Oncology Practice | April 14, 2023 | Volume: 19 | Issue: 6 | Pages: e877-e891

10.1200/op.22.00822 | PMID 37058684 Get It

PURPOSE: Clinical trials are important for managing older patients with AML. We investigated differences in outcomes of older patients with AML on the basis of whether patients participated in intensive chemotherapy trials at community versus academic cancer centers. METHODS: We used data from the Alliance for Clinical Trials in Oncology phase III trials that enrolled patients age ≥ 60 years with newly diagnosed AML between 1998 and 2002 in the Cancer and Leukemia Group B (CALGB) 9720 trial and between 2004 and 2006 in the CALGB 10201 trial. Centers funded by the NCI Community Oncology Research Program were identified as community cancer centers; others were designated as academic cancer centers. Logistic regression models and Cox proportional hazards models were used to compare 1-month mortality and overall survival (OS) by center type. RESULTS: Seventeen percent of the 1,170 patients were enrolled in clinical trials in community cancer centers. The study results demonstrated comparable rates of grade ≥3 adverse events (97% v 93%), 1-month mortality (19.1% v 16.1%), and OS (43.9% v 35.7% at 1 year) between community versus academic cancer centers, respectively. After adjusting for covariates, 1-month mortality (odds ratio, 1.40; 95% CI, 0.92 to 2.12; P = .11) and OS (hazard ratio, 1.04; 95% CI, 0.88 to 1.22; P = .67) were not statistically different among patients treated in community versus academic cancer centers. CONCLUSION: An older patient population, who have complex health care needs, can be successfully treated on intensive chemotherapy trials in select community cancer centers with outcomes comparable with that achieved at academic cancer centers.
Effect of Messaging Content on Engagement With a Short Messaging Service for Perioperative Smoking Cessation
Jose, Thulasee , Cha, Sarah , Graham, Amanda L. , Schroeder, Darrell R. , Warner, David O. , Warner, David O , Jose, Thulasee , Schroeder, Darrell , Graham, Amanda L , Amato, Michael S.

Mayo Clinic

Nicotine and Tobacco Research | April 14, 2023 | Volume: 25 | Issue: 8 | Pages: 1465-1473

10.1093/ntr/ntad061 | PMID 37058426 Get It

Abstract Introduction We determined whether a tobacco cessation intervention targeting brief perioperative abstinence (“quit for a bit”) increased engagement of surgical patients with treatment compared with an intervention targeting long-term postoperative abstinence (“quit for good”). Aims and Methods Surgical patients who smoke were stratified according to intended duration of postoperative abstinence, and then randomized within strata to receive either a “quit for a bit” or a “quit for good” intervention. Both employed initial brief counseling and short message service (SMS) to deliver treatment up to 30 days after surgery. The primary outcome of treatment engagement was defined as the rate at which subjects actively responded to system requests delivered via SMS. Results The engagement index did not differ between intervention groups (median [25th, 75th] of 23.7% [8.8, 46.0] for “quit for a bit” group (n = 48) and 22.2% [4.8, 46.0] for “quit for good” group (n = 50), p = .74), nor did the proportion of patients continuing SMS use after study completion (33% and 28%, respectively). Exploratory abstinence outcomes on the morning of surgery and 7 and 30 days after surgery did not differ between groups. Program satisfaction was high in both groups and did not differ. There was no significant interaction between intended abstinence duration and any outcome, ie, alignment of intent with intervention did not affect engagement. Conclusions Tobacco cessation treatment delivered via SMS was well accepted by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Implications Treatment of surgical patients for tobacco use is efficacious and reduces postoperative complications. However, implementation in clinical practice has proved challenging, and new methods of engaging these patients in cessation treatment are needed. We found that tobacco use treatment delivered via SMS was feasible and well utilized by surgical patients. Tailoring an SMS intervention to focus on the benefits of short-term abstinence for surgical patients did not increase engagement in treatment or perioperative abstinence rates. Clinical Trial Number NCT03839043. Registry URL: https://clinicaltrials.gov/ct2/show/NCT03839043
COUNTERPOINT: Pulmonary Vascular Resistance 2.0— Shedding Light or Casting Shadows?
Frantz, Robert P.

Mayo Clinic

Advances in Pulmonary Hypertension | April 14, 2023 | Volume: 22 | Issue: 1 | Pages: 67-70

10.21693/1933-088x-22.1.67 Get It

Risk factors for sacral fracture following en bloc chordoma resection
Mikula, Anthony L. , Pennington, Zach , Lakomkin, Nikita , Prablek, Marc , Karim, S. Mohammed, Patel, Shalin S. , Sciubba, Daniel M. , North, Robert Y. , Bydon, Mohamad , Fogelson, Jeremy L. , Elder, Benjamin D. , Krauss, William E. , Bird, Justin E. , Rose, Peter S. , Rhines, Laurence D. , Pennington, Zach , Amini, Behrang , Lubelski, Daniel , Alvarez‐Breckenridge, Christopher , Tatsui, Claudio Esteves , Clarke, Michelle J.

Mayo Clinic

Journal of Neurosurgery: Spine | April 14, 2023 | Volume: 39 | Issue: 5 | Pages: 611-617

10.3171/2023.3.spine221108 | PMID 37060308 Get It

OBJECTIVE The purpose of this study was to analyze risk factors for sacral fracture following noninstrumented partial sacral amputation for en bloc chordoma resection. METHODS A multicenter retrospective chart review identified patients who underwent noninstrumented partial sacral amputation for en bloc chordoma resection with pre- and postoperative imaging. Hounsfield units (HU) were measured in the S1 level. Sacral amputation level nomenclature was based on the highest sacral level with bone removed (e.g., S1 foramen amputation at the S1–2 vestigial disc is an S2 sacral amputation). Variables collected included basic demographics, patient comorbidities, surgical approach, preoperative radiographic details, neoadjuvant and adjuvant radiation therapy, and postoperative sacral fracture data. RESULTS A total of 101 patients (60 men, 41 women) were included; they had an average age of 69 years, BMI of 29 kg/m2, and follow-up of 60 months. The sacral amputation level was S1 (2%), S2 (37%), S3 (44%), S4 (9%), and S5 (9%). Patients had a posterior-only approach (77%) or a combined anterior–posterior approach (23%), with 10 patients (10%) having partial sacroiliac (SI) joint resection. Twenty-seven patients (27%) suffered a postoperative sacral fracture, all occurring between 1 and 7 months after the index surgery. Multivariable logistic regression analysis demonstrated S1 or S2 sacral amputation level (p = 0.001), combined anterior–posterior approach (p = 0.0064), and low superior S1 HU (p = 0.027) to be independent predictors of sacral fracture. The fracture rate for patients with superior S1 HU < 225, 225–300, and > 300 was 38%, 15%, and 9%, respectively. An optimal superior S1 HU cutoff of 300 was found to maximize sensitivity (89%) and specificity (42%) in predicting postamputation sacral fracture. In addition, the fracture rate for patients who underwent partial SI joint resection was 100%. CONCLUSIONS Patients with S1 or S2 partial sacral amputations, a combined anterior–posterior surgical approach, low superior S1 HU, and partial SI joint resection are at higher risk for postoperative sacral fracture following en bloc chordoma resection and should be considered for spinopelvic instrumentation at the index procedure.
What Is Marfan Syndrome?
Connolly, Heidi M. , Bowen, Juan M. , Niaz, Talha

Mayo Clinic

JAMA | April 14, 2023 | Volume: 329 | Issue: 18 | Pages: 1618

10.1001/jama.2023.3826 | PMID 37058316 Get It

This JAMA Patient Page describes the autosomal dominant genetic disorder of Marfan syndrome and its diagnosis and treatment.